198 related articles for article (PubMed ID: 31301455)
1. Seizure management and prescription patterns of anticonvulsants in Dravet syndrome: A multicenter cohort study from Germany and review of literature.
Schubert-Bast S; Wolff M; Wiemer-Kruel A; von Spiczak S; Trollmann R; Reif PS; Pritchard C; Polster T; Neubauer BA; Mayer T; Macdonald D; Kurlemann G; Kluger G; Klein KM; Kieslich M; Kay L; Kalski M; Irwin J; Herting A; Carroll J; Bettendorf U; Bast T; Rosenow F; Strzelczyk A
Epilepsy Behav; 2019 Sep; 98(Pt A):88-95. PubMed ID: 31301455
[TBL] [Abstract][Full Text] [Related]
2. Stiripentol in Dravet syndrome: results of a retrospective U.S. study.
Wirrell EC; Laux L; Franz DN; Sullivan J; Saneto RP; Morse RP; Devinsky O; Chugani H; Hernandez A; Hamiwka L; Mikati MA; Valencia I; Le Guern ME; Chancharme L; de Menezes MS
Epilepsia; 2013 Sep; 54(9):1595-604. PubMed ID: 23848835
[TBL] [Abstract][Full Text] [Related]
3. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome.
Aras LM; Isla J; Mingorance-Le Meur A
Epilepsy Behav; 2015 Mar; 44():104-9. PubMed ID: 25666511
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen.
Dressler A; Trimmel-Schwahofer P; Reithofer E; Mühlebner A; Gröppel G; Reiter-Fink E; Benninger F; Grassl R; Feucht M
Epilepsy Res; 2015 Jan; 109():81-9. PubMed ID: 25524846
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan.
Inoue Y; Ohtsuka Y;
Epilepsy Res; 2015 Jul; 113():90-7. PubMed ID: 25986195
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam.
Strzelczyk A; Schubert-Bast S; Reese JP; Rosenow F; Stephani U; Boor R
Epilepsy Behav; 2014 May; 34():86-91. PubMed ID: 24727467
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence.
Inoue Y; Ohtsuka Y;
Epilepsy Res; 2014 May; 108(4):725-31. PubMed ID: 24630050
[TBL] [Abstract][Full Text] [Related]
8. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood?
Chiron C; Helias M; Kaminska A; Laroche C; de Toffol B; Dulac O; Nabbout R; An I
Epilepsia; 2018 Sep; 59(9):1705-1717. PubMed ID: 30132836
[TBL] [Abstract][Full Text] [Related]
9. Stiripentol: A Review in Dravet Syndrome.
Frampton JE
Drugs; 2019 Nov; 79(16):1785-1796. PubMed ID: 31617141
[TBL] [Abstract][Full Text] [Related]
10. Patients with dravet syndrome in the era of stiripentol: A French cohort cross-sectional study.
De Liso P; Chemaly N; Laschet J; Barnerias C; Hully M; Leunen D; Desguerre I; Chiron C; Dulac O; Nabbout R
Epilepsy Res; 2016 Sep; 125():42-6. PubMed ID: 27389706
[TBL] [Abstract][Full Text] [Related]
11. Dravet syndrome: Treatment options and management of prolonged seizures.
Cross JH; Caraballo RH; Nabbout R; Vigevano F; Guerrini R; Lagae L
Epilepsia; 2019 Dec; 60 Suppl 3():S39-S48. PubMed ID: 31904119
[TBL] [Abstract][Full Text] [Related]
12. Changing Landscape of Dravet Syndrome Management: An Overview.
Samanta D
Neuropediatrics; 2020 Apr; 51(2):135-145. PubMed ID: 32079034
[TBL] [Abstract][Full Text] [Related]
13. Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome.
Morimoto M; Shimakawa S; Hashimoto T; Kitaoka T; Kyotani S
J Clin Pharm Ther; 2018 Aug; 43(4):571-573. PubMed ID: 29265387
[TBL] [Abstract][Full Text] [Related]
14. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials.
Bialer M; Perucca E
Epilepsia; 2020 Jun; 61(6):1082-1089. PubMed ID: 32452568
[TBL] [Abstract][Full Text] [Related]
15. Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications.
Lopez JC; Pare JR; Blackmer AB; Orth LE
J Pediatr Health Care; 2022; 36(5):479-488. PubMed ID: 35987555
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, matched case-control analysis comparing burden-of-illness in Dravet syndrome to refractory epilepsy and seizure remission in patients and caregivers in Germany.
Strzelczyk A; Schubert-Bast S; Bast T; Bettendorf U; Fiedler B; Hamer HM; Herting A; Kalski M; Kay L; Kieslich M; Klein KM; Kluger G; Kurlemann G; Mayer T; Neubauer BA; Polster T; von Spiczak S; Stephani U; Trollmann R; Wiemer-Kruel A; Wolff M; Irwin J; Carroll J; Pritchard C; Rosenow F
Epilepsia; 2019 Aug; 60(8):1697-1710. PubMed ID: 31247127
[TBL] [Abstract][Full Text] [Related]
17. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.
Chiron C; Marchand MC; Tran A; Rey E; d'Athis P; Vincent J; Dulac O; Pons G
Lancet; 2000 Nov; 356(9242):1638-42. PubMed ID: 11089822
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy for Dravet Syndrome.
Wallace A; Wirrell E; Kenney-Jung DL
Paediatr Drugs; 2016 Jun; 18(3):197-208. PubMed ID: 26966048
[TBL] [Abstract][Full Text] [Related]
19. Current therapeutic procedures in Dravet syndrome.
Chiron C
Dev Med Child Neurol; 2011 Apr; 53 Suppl 2():16-8. PubMed ID: 21504427
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes.
Shi XY; Tomonoh Y; Wang WZ; Ishii A; Higurashi N; Kurahashi H; Kaneko S; Hirose S;
Brain Dev; 2016 Jan; 38(1):40-6. PubMed ID: 26183863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
